Stock Analysis·← Pickers

PLRZ

Polyrizon Ltd.

Polyrizon Ltd. (PLRZ) is currently in a range/mixed trend, above the 200-day MA but below the 50-day MA. RSI is at 47.3, with 2/3 trend checks passing.

Price
$13.07
2026-07-16
Trend score
2/3
Range / Mixed
RSI (14)
47.3
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

PLRZ with MA50 and MA200

36.8128.3919.9711.553.1307/3110/2401/2204/1707/15
PLRZ2025-07-312026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$13.75-4.96% vs price
MA200
$11.41+14.52% vs price
RSI (14)
47.3Neutral zone
MACD Signal
BullishMomentum above signal
Macro Support
$10.37–$10.5019.7% below price · 2 touches
Support Quality
2 touches4.7× zone volume
Chart Summary
Trend summary for PLRZ

Polyrizon Ltd. (PLRZ) looks more range-bound than strongly trending, but there are still a few supportive signs on the chart. The latest available price is $13.07, and 2 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 5.0% and above the 200-day moving average by 14.5%.

Momentum and stretch context

PLRZ currently has an RSI reading of 47.3, which sits in a neutral range. That usually means momentum is not especially stretched in either direction, so traders may need to rely more on chart structure than on oscillator extremes alone.

What traders may watch next

This page is designed to help you quickly understand what the PLRZ chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.

Company profile

About Polyrizon Ltd.

Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.

Sector
Healthcare
Industry
Biotechnology
CEO
Tomer Izraeli
Employees
6
Market cap
$14.6M
Beta
-1.53
52-week range
$2.88 – $18.20
Dividend
No
Exchange
NASDAQ
Country
IL
IPO date
29 Oct 2024
ISIN
IL0011814113
CUSIP
M79549123
Company profile data from Financial Modeling Prep. PLRZ listed on NASDAQ.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about PLRZ

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.